Trials / Terminated
TerminatedNCT00813111
Phase 3 Study of Local Administration of SKY0402 for Postoperative Analgesia in Subject Undergoing Breast Augmentation
A Phase 3, Multicenter, Randomized, Double-blind Parallel-group, Active-control Study to Evaluate the Safety and Efficacy of Local Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Bilateral, Cosmetic Sub-muscular Breast Augmentation
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 136 (actual)
- Sponsor
- Pacira Pharmaceuticals, Inc · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to provide a more effective postoperative method of pain control for patients undergoing cosmetic sub-muscular breast augmentation. Appropriate postoperative pain management contributes to faster patient mobilization, shortened hospital stays, and reduced healthcare costs.
Detailed description
This is a phase 3 study conducted to evaluate the safety and efficacy of a single local administration of 300 mg of SKY0402 compared with 100 mg of conventional, commercially-available bupivacaine HCl (i.e. Marcaine 0.5% with epinephrine) administered locally into the implant pocket of each breast for postoperative analgesia in subjects undergoing bilateral, cosmetic, sub-muscular, breast augmentation under general anesthesia (endotracheal or otherwise). A total of 600 mg of SKY0402 or 200 mg bupivacaine HCl per subject is therefore administered. Post-operative assessments were conducted including adverse event and serious adverse event monitoring through Day 30.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SKY0402 | 600mg SKY0402 instilled into breast pocket during surgery |
| DRUG | Bupivacaine HCl | 200mg Bupivacaine HCl instilled into breast pocket during surgery |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2008-12-22
- Last updated
- 2014-01-16
- Results posted
- 2014-01-16
Locations
15 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00813111. Inclusion in this directory is not an endorsement.